Études & Programmes
La recherche sauve des vies
Status
Settings
Subtypes
Status
Settings
Subtypes
Others
Search
Male Breast Cancer
BIG 2-07
Clinical and Biological Characterization of Male Breast Cancer
HERA
BIG 1-01
Comparison of different regimes of trastuzumab for women with HER2-positive primary breast cancer
PANACEA
BIG 4-13
anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer
DECRESCENDO
BIG 19-02
De-escalation of adjuvant chemotherapy in HER2-positive, HR-negative breast cancer
AMEERA-6
BIG 20-01
Amcenestrant in patients with HR+, HER2-negative/positive breast cancer who experienced toxicities with aromatase inhibitors
BIG 1-98 / IBCSG 18-98
BIG 1-98
Letrozole or tamoxifen in treating postmenopausal women with breast cancer
ULTIMATE
BIG 16-01
Immunotherapy as neoadjuvant treatment in ER+/HER2-negative breast cancer
TREAT CTC
BIG 1-12
TRastuzumab treatment for HER2-negative early breast cancer in the presence of circulating tumor cells
SOFT / TEXT
BIG 2-02 / BIG 3-02
Testing different post-operative endocrine treatments for young women with hormone-sensitive breast cancer
SNAP
BIG 2-12
Evaluation of different schedules of nab-paclitaxel for metastatic breast cancer
LORELEI
BIG 3-13
Different regimes of letrozole (or letrozole + taselisib) in postmenopausal women with ER positive/HER2-negative, early stage breast cancer
BRAVO
BIG 5-13
Niraparib for patients with HER2-negative, germline BRCA mutation-positive breast cancer
SOLE
BIG 1-07
ontinuous versus intermittent letrozole following endocrine treatment for postmenopausal women with disease-free of hormone-receptor positive, node-positive early stage breast cancer
PENELOPE-B
BIG 1-13
Post-neoadjuvant palbociblib for patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk
PYTHIA
BIG 14-04
Palbociclib in molecularly characterised ER-positive/HER2-negative metastatic breast cancer
MA.32 Metformin
BIG 5-11
Effect of metformin on recurrence and survival in early stage breast cancer
OlympiA
BIG 6-13
Olaparib as adjuvant treatment in patients with germline BRCA-mutated high risk HER2 negative primary breast cancer (OlympiA)
POLAR
BIG 18-02
Palbociclib for HR+ isolated local or regional recurrence of breast cancer
Male Breast Cancer
BIG 2-07
Clinical and Biological Characterization of Male Breast Cancer
Exceptional Responders
BIG 16-04
A global hunt for Exceptional Responders in the BIG network
Breast Cancer in Pregnancy
BIG 2-03
Prospective Register Study for Diagnosis and Treatment of Breast Cancer in Pregnancy
NeoALTTO
BIG 1-06
Comparison of dual HER2 inhibition (lapatinib, trastuzumab) plus chemotherapy before surgery versus single HER2-targeted therapy
MINDACT
BIG 3-04
Can addition of 70-gene signature to common clinical-pathological criteria safely spare patients from adjuvant chemotherapy?
HERA
BIG 1-01
Comparison of different regimes of trastuzumab for women with HER2-positive primary breast cancer
EXPERT
BIG 16-02
EXamining PErsonalised Radiation Therapy for low-risk early breast cancer
DCIS
BIG 3-07
A randomized phase III study of radiation doses and fractionation schedules in non-low risk Ductal Carcinoma In Situ (DCIS) of the breast
POSITIVE
BIG 8-13
Endocrine therapy interruption to enable conception for young women with ER+ breast cancer
AURORA
BIG 14-01
Aiming to understand the molecular aberrations in metastatic breast cancer
APHINITY
BIG 4-11
Comparison of single-versus-dual anti-HER2 therapy (trastuzumab, pertuzumab) for patients with HER2-positive primary breast cancer
ALTTO
BIG 2-06
Adjuvant lapatinib and trastuzumab: sequence and combination for patients with HER2/ErbB2 positive primary breast cancer
ALEXANDRA IMpassion030
BIG 16-05
Comparison of adjuvant anti PD-L1 antibody (atezolizumab) plus chemotherapy versus chemotherapy alone in TNBC patients
